奎斯特诊断公司已从美国疾病控制与预防中心（CDC）获得多项合同协议，旨在增强针对新兴传染病的诊断准备和实验室响应能力。这些合同于2024年9月正式授予，包括专项资金用于开发奥罗普切病毒的检测方法。相关资金将确保公司维持测试物资和设备储备，以快速响应潜在公共卫生威胁。同时，奎斯特还推出了首个商业化的禽流感A H5诊断测试，进一步巩固其在传染病防控领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.